Woven Planet Holdings, a Subsidiary of Toyota, to Acquire CARMERA
15.7.2021 00:00:00 EEST | Business Wire | Press release
Woven Planet Holdings, Inc. (“Woven Planet”), a subsidiary of the Toyota Motor Corporation, announced the acquisition of CARMERA, Inc. (“CARMERA”), a U.S.-based spatial AI company, which specializes in bringing next-generation road intelligence to automated mobility at scale. This is the second major deal for Woven Planet in North America, following the April 2021 announcement to acquire Level 5, the self-driving division of Lyft.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210714005892/en/
Proof of Concept in Tokyo (Still) (Graphic: Business Wire)
Once the deal is closed, the CARMERA team will report into the Automated Mapping Platform (“AMP”) organization of Woven Alpha, Inc. (“Woven Alpha”). Woven Alpha focuses on exploring new strategic areas for business expansion and incubates several innovative projects such as Woven City and Arene, which is Woven Planet’s open software platform. AMP is a connected crowdsourced software platform that supports the creation, development and distribution of high definition (“HD”) maps—a key enabler for smart and safe automated mobility.
The Woven Alpha team plans to develop AMP to become the most globally comprehensive road and lane network HD map platform, enabling high-precision localization support to automated vehicles. The acquisition of CARMERA will accelerate AMP’s shift from the R&D stage to the next phase of commercialization by bolstering the platform’s engineering team with top experts in the development of HD maps. In addition, it will provide access to CARMERA’s sophisticated map update, change management and IoT sensing technology.
Together, the teams will tap into CARMERA’s ability to successfully update HD maps from crowdsourced, camera-based inputs—a significantly cheaper and faster approach than traditional methods. This will strengthen AMP’s ability to serve a comprehensive set of road classes and features, reflecting changes in lane markings, traffic signals, signs and more in near real-time, and support its future multi-regional commercial launch.
CARMERA will join Woven Planet Group as a wholly-owned subsidiary, expanding the company’s footprint beyond its Tokyo headquarters by adding New York and Seattle offices to its planned offices in Silicon Valley and London.
Comment from Mandali Khalesi, Vice President of Automated Driving Strategy and Mapping, Woven Planet:
“AMP has been a key project of Woven Planet since its foundation, helping support its vision of ‘Mobility to Love, Safety to Live.’ We’ve been progressing steadily in bringing safe automated mobility to the passenger and commercial vehicle segments, such as our recent announcements with Isuzu Motors Limited and Hino Motors, Ltd., and with Mitsubishi Fuso Truck and Bus Corporation. I’m really excited to welcome CARMERA to Woven Planet. With CARMERA joining the team, we’ll be able to hit the accelerator. CARMERA’s software stack, which is focused on real-time HD map changes and proprietary hardware custom-tailored to crowdsourcing, is an ideal complement to AMP’s mapping efforts. In addition, their world-class experts will allow us to bring forward the execution of key strategic milestones and jumpstart operations in the United States.”
Comment from Ro Gupta, CEO and Co-founder, CARMERA:
“Woven Planet and AMP have been highly aligned with CARMERA’s culture and mission from the beginning. Our teams have a common view of the unmet need for ubiquity in advanced mobility data going forward, including maps. Woven Planet, thanks to its software-first automotive DNA, shares our commitment to the end-user—to creating a technology stack that can be used safely and without friction by all stakeholders from data originators through to data consumers. This validates and furthers our founding thesis that richer, faster spatial intelligence is both critical to the next generation of ‘Mobility for All’ and viable at global-production scale. I’m beyond excited for CARMERA to join the Woven Planet organization, as it continues to strengthen its footprint in North America and ramp up its software-first development of mobility innovations.”
An earlier partnership between Woven Planet—under its predecessor organization Toyota Research institute - Advanced Development, Inc.—and CARMERA in Tokyo, Detroit and Ann Arbor, Michigan, laid the groundwork for this deal. Woven Planet and CARMERA participated in collaborative projects in 2018, 2019 and 2020, which proved the companies can successfully develop and update HD maps from commodity, device-agnostic sources, such as commercially available dashboard-mounted cameras.
About Woven Planet Group
Woven Planet Group represents a carefully curated blend of expertise and resources dedicated to bringing the vision of “Mobility to Love, Safety to Live” to life. Through innovations and investments in automated driving, robotics, smart cities, and more, we are transforming how humankind lives, works, and moves. We exist to design, build, and deliver secure, connected, and sustainable mobility solutions that benefit all people worldwide. Founded in 2018 as Toyota Research Institute - Advanced Development (TRI-AD), Woven Planet Group is composed of four complementary companies: Woven Planet Holdings, Woven Core, Woven Alpha, and Woven Capital.
For more information, please visit: https://www.woven-planet.global/
About CARMERA
CARMERA is a spatial AI company, built on the revolution of vehicular crowdsourcing and remote sensing to capture street-level change, at global breadth and high definition depth. CARMERA employs an open systems approach to working with the world’s leading automotive companies, commercial mobility operators, and mapping platforms. With a team hailing from leading geospatial, machine learning and computer vision organizations, and venture backing from GV (Google Ventures) among others, the company is headquartered in New York City and Seattle. CARMERA is the recipient of multiple industry awards, including Frost & Sullivan’s 2020 North American Mapping Company of the Year.
For more information, please visit: https://www.carmera.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005892/en/
Contact information
Woven Planet Holdings, Inc.
pr@woven-planet.global
https://www.woven-planet.global/
CARMERA, Inc.
press@carmera.com
https://www.carmera.com/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom